[The SWOG-8710/INT-0080 study: innovations and controversies concerning neoadjuvant treatment of locally advanced bladder cancer].
Nelli
Fabrizio
F
Ospedale Belcolle, Viterbo.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D015653:Cystectomy; D004317:Doxorubicin / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D015993:Life Tables; D015201:Meta-Analysis as Topic; D008727:Methotrexate / Q000008:administration & dosage; D015337:Multicenter Studies as Topic; D020360:Neoadjuvant Therapy; D011183:Postoperative Complications; D011292:Premedication; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D014747:Vinblastine / Q000008:administration & dosage
D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate